Article Text

Download PDFPDF

What's new in IL-12? Combination!
  1. Chris E Lawrence1,
  2. Mark Rubinstein2,
  3. Zoya Gluzman-Poltorak1,
  4. Vladimir Vainstein1 and
  5. Lena A Basile1
  1. Aff1 grid.436648.bNeumedicines Pasadena CA USA
  2. Aff2 grid.259828.c0000000121893475Medical University of South Carolina Charleston SC USA

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Meeting abstracts

IL-12 is a heterodimeric, pro-inflammatory cytokine that enhances the cytotoxic activity of natural killer (NK) cells and cytotoxic CD8+ T-lymphocytes, and induces an IFN-α-dominated Th1 CD4+ T-lymphocyte response. IL-12 as an immunotherapeutic agent administered subcutaneously in cancer patients has demonstrated clinical responses in melanoma, T cell lymphoma, non-Hodgkin's lymphoma, and AIDS-related Kaposi sarcoma, but was never developed further. Having elucidated novel hematological properties of IL-12, we are advancing our proprietary recombinant human IL-12 (NM-IL-12) for the treatment of the Hematopoietic Syndrome of Acute Radiation Syndrome. In three clinical safety studies conducted in over 200 healthy human volunteers, subcutaneous NM-IL-12 was well-tolerated. No adverse immune reactions or immunogenicity were observed.

We have now developed a novel clinical paradigm for the use of subcutaneously administered, low dose NM-IL-12 combined with standard of care radiotherapy, chemotherapy, or immunotherapy for the treatment of cancer. The pleiotropic effects of IL-12 are expected to augment the mechanistic, anti-tumor effects of each of these treatments.

In vitro NM-IL-12 stimulated primary human NK cell secretion of IFN-g and the cytotoxic lysis of leukemic cells, and inhibited production of pro-angiogenic IL-17 in human peripheral blood mononuclear cells. In vivo, recombinant murine IL-12 (rMuIL-12) caused significant tumor growth inhibition following total body irradiation (625cGy) in syngeneic Lewis lung and EL4 lymphoma tumor models. In the same models, rMuIL-12 in combination with cyclophosphamide also caused significant tumor growth inhibition. In the case of the non-immunogenic Lewis lung cancer model the combination of chemotherapy and IL-12 enhanced immunogenicity. In both tumor models, the antitumor effects of IL-12 were accompanied by rapid recovery of neutrophils, platelets and red blood cells, depressed by radiation or chemotherapy. This suggests an additional benefit of NM-IL-12 to cancer patients myelosuppressed following radiation or chemotherapy.

Preclinical evaluation of NM-IL-12 with radiation therapy and chemotherapy is now followed by evaluating combination immunotherapy. PD-1 blockade elicits potent anti-tumor immunity in a subset of melanoma patients. We have thus evaluated the combination of rMuIL-12 and anti-PD-1 antibody in a clinically relevant, syngeneic model of spontaneous, highly metastatic B16 mouse melanoma has been tested.

In summary we show that NM-IL-12 has excellent anti-tumor potential when used preclinically in combination with standard of care anti-cancer treatments, including radiation, chemotherapy and immunotherapy. NM-IL-12 is expected to contribute durable anti-tumor responses in the clinic through potent immunoactivation and anti-angiogenic effects, and to replenish blood cells, while being safe, well tolerated and non-immunogenic.